Estradiol	0	9	B-Drug_or_compound
increases	10	19	O
IL	20	22	B-Gene_or_gene_product
-	22	23	I-Gene_or_gene_product
8	23	24	I-Gene_or_gene_product
secretion	25	34	O
of	35	37	O
normal	38	44	O
human	45	50	B-Organism
breast	51	57	B-Tissue
tissue	58	64	I-Tissue
and	65	68	O
breast	69	75	B-Pathological_formation
cancer	76	82	I-Pathological_formation
in	83	85	O
vivo	86	90	O
.	90	91	O

IL	93	95	B-Gene_or_gene_product
-	95	96	I-Gene_or_gene_product
8	96	97	I-Gene_or_gene_product
or	98	100	O
CXCL8	101	106	B-Gene_or_gene_product
has	107	110	O
been	111	115	O
associated	116	126	O
with	127	131	O
tumor	132	137	B-Pathological_formation
angiogenesis	138	150	O
,	150	151	O
metastasis	152	162	O
,	162	163	O
and	164	167	O
poor	168	172	O
prognosis	173	182	O
in	183	185	O
breast	186	192	B-Pathological_formation
cancer	193	199	I-Pathological_formation
.	199	200	O

Estrogen	201	209	B-Drug_or_compound
is	210	212	O
crucial	213	220	O
in	221	223	O
breast	224	230	B-Organism_subdivision
carcinogenesis	231	245	O
and	246	249	O
tumor	250	255	B-Pathological_formation
progression	256	267	O
.	267	268	O

Whether	269	276	O
sex	277	280	O
steroids	281	289	O
affect	290	296	O
IL	297	299	B-Gene_or_gene_product
-	299	300	I-Gene_or_gene_product
8	300	301	I-Gene_or_gene_product
secretion	302	311	O
of	312	314	O
normal	315	321	O
breast	322	328	B-Tissue
tissue	329	335	I-Tissue
or	336	338	O
breast	339	345	B-Pathological_formation
cancer	346	352	I-Pathological_formation
is	353	355	O
not	356	359	O
known	360	365	O
.	365	366	O

Several	367	374	O
cell	375	379	B-Cell
types	380	385	O
in	386	388	O
a	389	390	O
tissue	391	397	B-Tissue
secrete	398	405	O
IL	406	408	B-Gene_or_gene_product
-	408	409	I-Gene_or_gene_product
8	409	410	I-Gene_or_gene_product
.	410	411	O

Hence	412	417	O
,	417	418	O
regulatory	419	429	O
mechanisms	430	440	O
of	441	443	O
IL	444	446	B-Gene_or_gene_product
-	446	447	I-Gene_or_gene_product
8	447	448	I-Gene_or_gene_product
need	449	453	O
to	454	456	O
be	457	459	O
investigated	460	472	O
in	473	475	O
whole	476	481	O
tissue	482	488	B-Tissue
.	488	489	O

We	490	492	O
used	493	497	O
microdialysis	498	511	O
to	512	514	O
sample	515	521	O
IL	522	524	B-Gene_or_gene_product
-	524	525	I-Gene_or_gene_product
8	525	526	I-Gene_or_gene_product
in	527	529	O
normal	530	536	O
human	537	542	B-Organism
breast	543	549	B-Tissue
tissue	550	556	I-Tissue
in	557	559	O
situ	560	564	O
in	565	567	O
pre	568	571	O
-	571	572	O
and	573	576	O
postmenopausal	577	591	O
women	592	597	B-Organism
,	597	598	O
preoperatively	599	613	O
in	614	616	O
breast	617	623	B-Pathological_formation
cancers	624	631	I-Pathological_formation
of	632	634	O
women	635	640	B-Organism
,	640	641	O
and	642	645	O
in	646	648	O
experimental	649	661	B-Pathological_formation
breast	662	668	I-Pathological_formation
cancer	669	675	I-Pathological_formation
in	676	678	O
mice	679	683	B-Organism
.	683	684	O

We	685	687	O
found	688	693	O
a	694	695	O
significant	696	707	O
positive	708	716	O
correlation	717	728	O
between	729	736	O
IL	737	739	B-Gene_or_gene_product
-	739	740	I-Gene_or_gene_product
8	740	741	I-Gene_or_gene_product
and	742	745	O
estradiol	746	755	B-Drug_or_compound
in	756	758	O
normal	759	765	O
breast	766	772	B-Tissue
tissue	773	779	I-Tissue
and	780	783	O
hormone	784	791	B-Pathological_formation
-	791	792	I-Pathological_formation
dependent	792	801	I-Pathological_formation
breast	802	808	I-Pathological_formation
cancer	809	815	I-Pathological_formation
in	816	818	O
vivo	819	823	O
.	823	824	O

Ex	825	827	O
vivo	828	832	O
,	832	833	O
estradiol	834	843	B-Drug_or_compound
exposure	844	852	O
increased	853	862	O
the	863	866	O
IL	867	869	B-Gene_or_gene_product
-	869	870	I-Gene_or_gene_product
8	870	871	I-Gene_or_gene_product
secretion	872	881	O
of	882	884	O
normal	885	891	O
whole	892	897	O
breast	898	904	B-Tissue
tissue	905	911	I-Tissue
in	912	914	O
culture	915	922	O
.	922	923	O

In	924	926	O
experimental	927	939	O
breast	940	946	B-Pathological_formation
cancer	947	953	I-Pathological_formation
,	953	954	O
estradiol	955	964	B-Drug_or_compound
increased	965	974	O
IL	975	977	B-Gene_or_gene_product
-	977	978	I-Gene_or_gene_product
8	978	979	I-Gene_or_gene_product
whereas	980	987	O
the	988	991	O
anti	992	996	O
-	996	997	O
estrogen	997	1005	O
tamoxifen	1006	1015	B-Drug_or_compound
inhibited	1016	1025	O
the	1026	1029	O
secretion	1030	1039	O
of	1040	1042	O
IL	1043	1045	B-Gene_or_gene_product
-	1045	1046	I-Gene_or_gene_product
8	1046	1047	I-Gene_or_gene_product
both	1048	1052	O
in	1053	1055	O
vitro	1056	1061	O
and	1062	1065	O
extracellularly	1066	1081	O
in	1082	1084	O
vivo	1085	1089	O
in	1090	1092	O
tumors	1093	1099	B-Pathological_formation
of	1100	1102	O
nude	1103	1107	B-Organism
mice	1108	1112	I-Organism
.	1112	1113	O

An	1114	1116	O
anti	1117	1121	B-Drug_or_compound
-	1121	1122	I-Drug_or_compound
IL	1122	1124	I-Drug_or_compound
-	1124	1125	I-Drug_or_compound
8	1125	1126	I-Drug_or_compound
Ab	1127	1129	I-Drug_or_compound
inhibited	1130	1139	O
endothelial	1140	1151	B-Cell
cell	1152	1156	I-Cell
proliferation	1157	1170	O
induced	1171	1178	O
by	1179	1181	O
cancer	1182	1188	B-Cell
cell	1189	1193	I-Cell
produced	1194	1202	O
IL	1203	1205	B-Gene_or_gene_product
-	1205	1206	I-Gene_or_gene_product
8	1206	1207	I-Gene_or_gene_product
and	1208	1211	O
tumors	1212	1218	B-Pathological_formation
with	1219	1223	O
low	1224	1227	O
IL	1228	1230	B-Gene_or_gene_product
-	1230	1231	I-Gene_or_gene_product
8	1231	1232	I-Gene_or_gene_product
levels	1233	1239	O
exhibited	1240	1249	O
decreased	1250	1259	O
angiogenesis	1260	1272	O
.	1272	1273	O

Our	1274	1277	O
results	1278	1285	O
strongly	1286	1294	O
suggest	1295	1302	O
that	1303	1307	O
estradiol	1308	1317	B-Drug_or_compound
has	1318	1321	O
a	1322	1323	O
critical	1324	1332	O
role	1333	1337	O
in	1338	1340	O
the	1341	1344	O
regulation	1345	1355	O
of	1356	1358	O
IL	1359	1361	B-Gene_or_gene_product
-	1361	1362	I-Gene_or_gene_product
8	1362	1363	I-Gene_or_gene_product
in	1364	1366	O
normal	1367	1373	O
human	1374	1379	B-Organism
breast	1380	1386	B-Tissue
tissue	1387	1393	I-Tissue
and	1394	1397	O
human	1398	1403	B-Organism
breast	1404	1410	B-Pathological_formation
cancer	1411	1417	I-Pathological_formation
.	1417	1418	O

IL	1419	1421	B-Gene_or_gene_product
-	1421	1422	I-Gene_or_gene_product
8	1422	1423	I-Gene_or_gene_product
may	1424	1427	O
present	1428	1435	O
a	1436	1437	O
novel	1438	1443	O
therapeutic	1444	1455	O
target	1456	1462	O
for	1463	1466	O
estrogen	1467	1475	B-Drug_or_compound
driven	1476	1482	O
breast	1483	1489	B-Organism_subdivision
carcinogenesis	1490	1504	O
and	1505	1508	O
tumor	1509	1514	B-Pathological_formation
progression	1515	1526	O
.	1526	1527	O

